Medicare Enrolled

Dr. Christopher Maisel, MD

Hematology & Oncology · Dallas, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
3410 WORTH ST, Dallas, TX 75246
2143701000
In practice since 2006 (19 years)
NPI: 1275575185 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Maisel from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Maisel? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Maisel

Dr. Christopher Maisel is a hematology & oncology in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. Maisel performed 25,745 Medicare services across 1,934 unique beneficiaries.

Between the years covered by Open Payments, Dr. Maisel received a total of $774,627 from 47 pharmaceutical and/or device companies across 827 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Maisel is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 31% volume in TX$ $774,627 industry payments

Medicare Practice Summary

Medicare Utilization ↗
25,745
Medicare services
Top 31% in TX for hematology & oncology
1,934
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,355 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Pembrolizumab injection (Keytruda)7,600$43$137
Contrast dye for imaging (iodine-based)4,900$0$3
Anti-nausea injection (fosaprepitant)4,350$0$5
Paclitaxel chemotherapy injection3,438$0$8
Dexamethasone injection (steroid)869$0$1
Blood draw (venipuncture)530$8$20
Complete blood count (CBC) with differential511$8$36
Anti-nausea injection (Aloxi/palonosetron)480$1$114
Injection, granisetron hydrochloride, 100 mcg420$0$24
Office visit, established patient (30-39 min)414$91$368
Comprehensive metabolic blood panel309$10$64
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less158$23$157
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg154$3$373
Administration of chemotherapy into vein, 1 hour or less138$103$707
Measurement of immunoglobulin light chains134$16$60
Injection, carboplatin, 50 mg121$2$300
Ferritin level test (iron stores)119$13$60
Injection of additional new drug or substance into vein117$12$108
Office visit, established patient (20-29 min)89$64$250
Microscopic examination for white blood cells with manual cell count76$4$22
Complete blood count (CBC), automated76$6$34
Injection, zoledronic acid, 1 mg61$7$431
Office visit, established patient, complex (40-54 min)58$137$496
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle52$58$211
Administration of additional new drug or substance into vein, 1 hour or less52$52$344
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less47$49$313
Injection, diphenhydramine hcl, up to 50 mg46$1$7
Ct scan of chest with contrast43$59$821
Drug injection, under skin or into muscle43$11$96
CT scan of abdomen and pelvis with contrast35$187$1,067
Hospital follow-up visit, high complexity35$92$357
Lactate dehydrogenase (enzyme) level34$6$31
Reticulated (young) platelet measurement34$35$143
Unclassified drugs34$1$8
Administration of chemotherapy into vein, each additional hour27$23$161
Hospital follow-up visit, moderate complexity24$62$247
Basic metabolic blood panel21$8$49
Infusion, normal saline solution , 1000 cc20$2$19
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour18$16$100
New patient office visit (45-59 min)16$125$565
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion15$16$94
New patient office visit, complex (60-74 min)15$174$709
CT scan of chest, without contrast12$50$686
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.0% high complexity
89.0% medium
10.0% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$774,627
Total received (2018-2024)
Avg $110,661/year across 7 years
Top 1% in TX for hematology & oncology
47
Companies
827
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$732,983 (94.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$38,480 (5.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,163 (0.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$86,640
2023
$130,347
2022
$146,093
2021
$69,690
2020
$106,155
2019
$108,326
2018
$127,375

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Kite Pharma, Inc.
$120,730
Blueprint Medicines Corporation
$99,527
Janssen Biotech, Inc.
$81,098
Karyopharm Therapeutics Inc.
$76,002
Incyte Corporation
$74,449
ADC Therapeutics America, Inc.
$70,027
Celgene Corporation
$52,972
Amgen Inc.
$42,643
Takeda Pharmaceuticals U.S.A., Inc.
$40,907
E.R. Squibb & Sons, L.L.C.
$39,627
GlaxoSmithKline, LLC.
$23,545
Verastem, Inc.
$15,439
AstraZeneca Pharmaceuticals LP
$15,137
Janssen Scientific Affairs, LLC
$13,469
Gilead Sciences, Inc.
$2,814
Genentech USA, Inc.
$2,727
Bayer HealthCare Pharmaceuticals Inc.
$1,140
GENZYME CORPORATION
$328
Rigel Pharmaceuticals, Inc.
$180
ABBVIE INC.
$160
SOBI, INC
$133
Novartis Pharmaceuticals Corporation
$132
PFIZER INC.
$128
Emmaus Medical, Inc.
$122
Adaptive Biotechnologies Corporation
$113
Seagen Inc.
$107
CTI BioPharma Corp.
$92
JAZZ PHARMACEUTICALS INC.
$87
SERVIER PHARMACEUTICALS LLC
$87
PharmaEssentia USA Corporation
$79
Siemens Medical Solutions USA, Inc.
$79
BeiGene USA, Inc.
$67
Lilly USA, LLC
$64
Merck Sharp & Dohme LLC
$57
Ipsen Biopharmaceuticals, Inc
$53
Dova Pharmaceuticals
$48
MorphoSys, US Inc.
$38
Genmab U.S., Inc.
$32
Epizyme, Inc.,
$32
Astellas Pharma US Inc
$31
AbbVie Inc.
$24
Daiichi Sankyo Inc.
$23
Sobi, Inc
$20
RECORDATI_RARE_DISEASES_INC.
$17
AbbVie, Inc.
$15
Taiho Oncology, Inc.
$14
Tactile Systems Technology Inc
$13
Top 3 companies account for 38.9% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · ALTUVIIIO · AYVAKIT · Aliqopa · BESREMI · BLENREP · BOSULIF · BRUKINSA · Blincyto · CALQUENCE · CARVYKTI · Copiktra · DARZALEX · DOPTELET · Doptelet · ELREXFIO · ENJAYMO · EPKINLY · Endari · Epkinly · Flexitouch Plus · Gamifant · ICLUSIG · IMBRUVICA · INREBIC · JAKAFI · JAYPIRCA · KEYTRUDA · Kyprolis · LONSURF · MONJUVI · Molecular Accessories · Molecular Reagents/Test Kit/Clinical Utilization · NINLARO · Neulasta · OJJAARA · ONGLYZA · ONUREG · PROMACTA · Pomalyst · REBLOZYL · Revlimid · Rezlidhia · Rituxan · SARCLISA · SCEMBLIX · SYLVANT · TAGRISSO · TASIGNA · TAZVERIK · TECVAYLI · Tavalisse · Tazverik · Tecartus · Tibsovo · VELCADE · VENCLEXTA · VERZENIO · VONJO · VYXEOS · Venclexta · Vonjo · XGEVA · XPOVIO · Xospata · Yescarta · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (95%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for hematology & oncology in TX.

Equivalent to $3,009 per 100 Medicare services performed
Looking for a hematology & oncology in Dallas?
Compare hematology & oncologys in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncologys nearby

Geographic Context

Hematology & Oncologys within 10 mi
129
Per 100K population
5.0
County median income
$74,149
Nearest hospital
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Maisel is a mixed practice specialist, with moderate Medicare volume, and high industry engagement (speaking/promotional, top 1%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Maisel experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Maisel performed 7,600 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Maisel receive payments from pharmaceutical companies?
Yes. Dr. Maisel received a total of $774,627 from 47 companies across 827 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Maisel's costs compare to other hematology & oncologys in Dallas?
Dr. Maisel's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Maisel) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →